In the new millennium, the biopharmaceutical industry has undergone a significant transformation in all areas of business. Blockbuster drugs, the foundation of the biologics revolution, are becoming increasingly rare. Many companies have experienced considerable setbacks within their clinical-trial programs. As a result, biopharmaceutical executives are faced with the ever-present dilemma of optimizing investment opportunities focused on advancing as many clinical prospects as practically and financially feasible. Focusing on medicines for broad patient populations no longer guarantees business success. Therefore, companies are identifying techniques and approaches that give an edge to the potential approval of a clinical candidate. One such approach is the use of translational sciences, particularly biomarker research. One outcome of using this novel approach is the development of more personalized, targeted medicines serving smaller patient populations.
CURRENT PRESSURES ON FACILITIES
The integration of biomarker data into the development process potentially promises less risky clinical-
MedImmune's Frederick Manufacturing Center (FMC), located in Frederick, Maryland, offers one example of how a
MEDIMMUNE'S FMC FACILITY
The first manufacturing building (B636) at FMC was constructed in the mid-1990s and commissioned to manufacture Synagis (palivizumab), a monoclonal antibody. Building 636 has 2 × 2.5k L bioreactors and associated proportional downstream purification capacity. The FMC was expanded in 2006 with the initiation of construction for B633, a large-scale (4 × 15k L bioreactors) mammalian cell culture-based commercial production facility initially designated for the manufacture of a mix of products in the pipeline at the time. As part of the design, MedImmune introduced a degree of flexibility to the facility, enabling it to potentially accommodate a range of product titers.
But one year after groundbreaking, the shape and magnitude of MedImmune's pipeline changed significantly. That same year, AstraZeneca acquired MedImmune and integrated the capabilities of Cambridge Antibody Technology (CAT), which AstraZeneca had acquired in 2006, into MedImmune's existing R&D infrastructure. Seemingly overnight, MedImmune's investigational pipeline jumped from approximately 40 candidates to more than 120 candidates, resulting in a fundamental shift for FMC from a single commercial product facility to a clinical and commercial multiproduct facility.
Addressing this situation required the company to overcome three key challenges as described below.